Literature DB >> 23946725

Cardiorenal syndrome type 4: a review.

Anna Clementi, Grazia Maria Virzì, Ching Yan Goh, Dinna N Cruz, Antonio Granata, Girogio Vescovo, Claudio Ronco.   

Abstract

There is a bidirectional and complex relationship between the heart and kidneys. This interaction is physical, chemical as well as biological and is also reflected in a strong connection between renal and cardiovascular diseases. Cardiorenal syndrome type 4 (CRS type 4) is characterized by primary chronic kidney disease (CKD) leading to an impairment of cardiac function, with ventricular hypertrophy, diastolic dysfunction, and/or increased risk of adverse cardiovascular events. The incidence of CKD is increasing, and CRS type 4 is becoming a major public health problem associated with a high morbidity and mortality. In this study, we briefly review the epidemiology and pathophysiology of CRS type 4, the role of biomarkers in its early identification, and its management.

Entities:  

Keywords:  Biomarkers; Cardiorenal syndrome type 4; Cardiovascular events; Chronic kidney disease

Year:  2013        PMID: 23946725      PMCID: PMC3743409          DOI: 10.1159/000350397

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  67 in total

Review 1.  Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients.

Authors:  Rajiv Agarwal; Matthew R Weir
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

2.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

3.  Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality.

Authors:  Andrea Gerdemann; Zoltan Wagner; Andreas Solf; Udo Bahner; August Heidland; Jörg Vienken; Reinhard Schinzel
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

4.  Cardiovascular disease risk factors in chronic renal insufficiency.

Authors:  M J Sarnak; B E Coronado; T Greene; S R Wang; J W Kusek; G J Beck; A S Levey
Journal:  Clin Nephrol       Date:  2002-05       Impact factor: 0.975

Review 5.  Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?

Authors:  Peter Stenvinkel; Peter Barany; Olof Heimbürger; Roberto Pecoits-Filho; Bengt Lindholm
Journal:  Kidney Int Suppl       Date:  2002-05       Impact factor: 10.545

6.  Cardiac troponin T predicts mortality in patients with end-stage renal disease.

Authors:  J Dierkes; U Domröse; S Westphal; A Ambrosch; H P Bosselmann; K H Neumann; C Luley
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

7.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

Authors:  J Zimmermann; S Herrlinger; A Pruy; T Metzger; C Wanner
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

8.  Enhanced production of nitric oxide by blood-dialysis membrane interaction.

Authors:  A Amore; R Bonaudo; D Ghigo; M Arese; C Costamagna; P Cirina; B Gianoglio; L Perugini; R Coppo
Journal:  J Am Soc Nephrol       Date:  1995-10       Impact factor: 10.121

9.  Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.

Authors:  Patrick H Pun; Ruediger W Lehrich; Stephen R Smith; John P Middleton
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-14       Impact factor: 8.237

10.  Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong.

Authors:  Claudio Ronco; Andrew A House; Mikko Haapio
Journal:  Intensive Care Med       Date:  2008-02-05       Impact factor: 17.440

View more
  16 in total

Review 1.  Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.

Authors:  Yoshitsugu Obi; Taehee Kim; Csaba P Kovesdy; Alpesh N Amin; Kamyar Kalantar-Zadeh
Journal:  Cardiorenal Med       Date:  2015-11-06       Impact factor: 2.041

Review 2.  Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.

Authors:  Srisakul Chirakarnjanakorn; Sankar D Navaneethan; Gary S Francis; W H Wilson Tang
Journal:  Int J Cardiol       Date:  2017-01-04       Impact factor: 4.164

Review 3.  Cellular apoptosis in the cardiorenal axis.

Authors:  Grazia Maria Virzì; Anna Clementi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

4.  Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.

Authors:  Rasha M S M Mohamed; Shimaa M Elshazly; Ola E Nafea; Dalia M Abd El Motteleb
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-16       Impact factor: 3.000

5.  Delayed kidney injury following coronary angiography.

Authors:  Feng Wang; Cheng Peng; Guangyuan Zhang; Qing Zhao; Changyou Xuan; Meng Wei; Niansong Wang
Journal:  Exp Ther Med       Date:  2016-05-09       Impact factor: 2.447

6.  miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells.

Authors:  Victoria L Nasci; Sandra Chuppa; Lindsey Griswold; Kathryn A Goodreau; Ranjan K Dash; Alison J Kriegel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-01-18       Impact factor: 4.733

7.  Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease.

Authors:  Il Young Kim; Byung Min Ye; Min Jeong Kim; Seo Rin Kim; Dong Won Lee; Hyo Jin Kim; Harin Rhee; Sang Heon Song; Eun Young Seong; Soo Bong Lee
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

8.  Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis.

Authors:  Grazia Maria Virzì; Anna Clementi; Massimo de Cal; Alessandra Brocca; Sonya Day; Silvia Pastori; Chiara Bolin; Giorgio Vescovo; Claudio Ronco
Journal:  Oxid Med Cell Longev       Date:  2015-03-04       Impact factor: 6.543

Review 9.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

10.  Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition.

Authors:  Yang Liu; Yu Liu; Xun Liu; Jie Chen; Kun Zhang; Feifei Huang; Jing-Feng Wang; Wanchun Tang; Hui Huang
Journal:  J Am Heart Assoc       Date:  2015-06-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.